@article{a44c3090983c45158cf261bb7a4c6035,
title = "Editorial commentary: Enterococcus faecalis infective endocarditis: Is it time to abandon aminoglycosides?",
keywords = "Enterococcus faecalis, aminoglycosides, high-level resistance, infective endocarditis",
author = "Munita, {Jose M.} and Arias, {Cesar A.} and Murray, {Barbara E.}",
note = "Funding Information: received lecture fees from Pfizer, Cubist, and Novartis; consulting fees from Pfizer and Cubist; and research support from Pfizer, Forest Pharmaceuticals, and Theravance. B. E. M. received grant support from Johnson & Johnson, Astellas, Forest, Theravance, and Cubist, and has served as consultant for Astellas (Theravance), Cubist, Targanta Therapeutics (now owned by The Medicines Company), Pfizer, Achaogen, Glaxo-SmithKline, The Medicines Company, Rib-X, and Durata Therapeutics. J. M. M. certifies no potential conflicts of interest.",
year = "2013",
month = may,
day = "1",
doi = "10.1093/cid/cit050",
language = "English (US)",
volume = "56",
pages = "1269--1272",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",
}